Mazdutide

Name: Mazdutide — Peptide Information
Creator: Michael Carroll

Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.

Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards

Weight ManagementResearch compound

Suggested dose

1.5 – 6 mg

1.5 mg
Initial titration weeks
4 mg
Maintenance (32-48 weeks in trial)
6 mg
Maintenance (32-48 weeks in trial)

Once dailyCycle: Ongoing/indefiniteOnset: Moderate (1-2 weeks)

Approximately 8 daysHalf-life

Subcutaneous bioavailability characteristic of acylated peptide analogsBioavailability

4563.1 DaMolecular weight

Strong human trialsEvidence level

Compound profile

Scientific & efficacy data

Weight Management

Peptide profile

Weight Loss9.8

Blood Sugar Control9.6

Metabolic Health9.0

Strong human trials

Mazdutide

1.5 mg · Once daily

Molecular formula

C₂₁₀H₃₂₂N₄₆O₆₇

Mol. weight: 4563.1 Da
CAS number: 2259884-03-0
PubChem: 167312357
Developed · 2023: Eli Lilly and Innovent Biologics
Eli Lilly and Company / Innovent Biologics

Amino acid sequence

37-amino acid oxyntomodulin analog with Aib2 substitution and C18 diacid fatty acid acylation via PEG2 linker at Lys10

Weight Loss

Phase 3 trials demonstrate up to 20.1% body weight reduction, among the highest in the dual agonist class [7][8].

Blood Sugar Control

Statistically superior HbA1c reductions versus both semaglutide and dulaglutide in head-to-head comparisons [1][15].

Metabolic Health

Glucagon receptor component drives hepatic fat reduction and improvements in lipid profiles beyond pure GLP-1 agonists [5][18].

Dosing

How much do I take?

1.5 mg, titrated to 6 mg · once weekly

1.5 – 6 mg

Once weekly

Full Mazdutide dosing protocol

Covers all 3 documented dose levels · timing · dose-adjustment guidance.

MazdutideOnce weekly

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to mg — like "5 mg".

Type a number to continue.

Suitability

Is this right for me?

Best for individuals seeking substantial weight loss exceeding 15% body weight & adults with type 2 diabetes requiring superior glycemic management

Best for

Individuals seeking substantial weight loss exceeding 15% body weight

Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. [6][7] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Adults with type 2 diabetes requiring superior glycemic management

Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. [1][15] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients with obesity-related metabolic comorbidities

Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. [6][18] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Those seeking dual-mechanism metabolic therapy

Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. [4][5] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for weight management supportConsult your healthcare provider for alternatives to Mazdutide based on your specific needs and medical history

Alternative weight management approachesSemaglutide (Wegovy/Ozempic), Liraglutide (Saxenda), AOD-9604

Non-injectable weight managementOral semaglutide (Rybelsus), Phentermine-topiramate (Qsymia), Lifestyle modifications

Do not use if

Personal or family history of medullary thyroid carcinoma or MEN2 syndromeKnown hypersensitivity to mazdutide or any formulation excipientsHistory of severe pancreatitisSevere renal impairment (eGFR <15 mL/min) without clinical data

Use with caution if

You are taking other medications—discuss potential interactions with your healthcare providerYou have a history of liver or kidney diseaseYou are elderly or have multiple medical conditionsYou are planning surgery in the near future—inform your surgeon about Mazdutide useYou have any chronic health conditions that require regular monitoring

Not sure?

Compare Mazdutide with similar peptides to find the best fit for your goals.

Mazdutide vs Semaglutide Mazdutide vs Tirzepatide Mazdutide vs Retatrutide

Administration

How do I use it?

Subcutaneous injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injectionFront of thighs—middle to upper portion of the outer legBack of upper arm—outer area (may need assistance from another person)

Mazdutide dosing protocol Mazdutide injection guide

Covers reconstitution · step-by-step technique · storage · a sample daily schedule.

Safety

Is it safe?

3 common side effects · 2 serious

Mazdutide (Roche/Carmot GLP-1/GCG/GIP triple agonist) completed Phase Ib with generally favorable safety profile but dose-limiting gastrointestinal side effects.

[11] Nausea/vomiting occur in 40-50% of subjects at higher doses; [7][12] weight loss averaging 12-18% observed. [6][7] Pancreatitis risk monitoring required; [9][10] calcitonin elevation consistent with GCG activation. Heart rate increases 5-8 bpm; no serious cardiac safety signals.

Developmental program focuses on tolerability optimization.

Phase Ib data demonstrate triple receptor mechanism with dose-dependent HbA1c reductions (1.2-1.8%) [13][10] and weight loss superior to GLP-1 monotherapy. [1][15] Mechanistic studies using indirect calorimetry show increased energy expenditure and fat oxidation.

[5][18] Pancreatic imaging via MRI shows no structural abnormalities; serum lipase monitored for pancreatitis risk. [9][10] Cardiovascular safety assessed via 24-hour ambulatory ECG shows sinus tachycardia without arrhythmias.

Common side effects · experienced by some users

Nausea
Most commonly reported adverse event, particularly during titration. Typically transient and self-limiting within 2-4 weeks [7][12].
Management: Slow dose titration, eat smaller meals, avoid high-fat foods, and stay hydrated.
Diarrhea
Occurs in a significant proportion of patients, generally mild to moderate in intensity [7][10].
Management: Maintain adequate fluid intake, consider temporary dietary modification, and consult prescriber if persistent.
Decreased Appetite
Pharmacological effect contributing to weight loss. [2][10] Considered therapeutic but may require nutritional monitoring.
Management: Ensure adequate protein and micronutrient intake despite reduced appetite. Consider dietitian consultation.

Less common

VomitingInjection Site Reactions

These typically resolve with continued use or dose adjustment.

Stop and seek help if

Severe or worsening side effects that don't improve with dose adjustment or supportive care
Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
Your healthcare provider recommends discontinuation based on your clinical response
Development of any new medical condition that may be contraindicated with Mazdutide
Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
Abnormal lab results or clinical markers that suggest adverse effects

Mazdutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

With other peptides

Safe:Metformin — May be used together under medical guidance.
Safe:Structured Exercise Program — May be used together under medical guidance.
Safe:SGLT2 Inhibitors — May be used together under medical guidance.

With medications

Caution:Other GLP-1 Receptor Agonists — Use with caution—discuss with your healthcare provider.
Caution:Sulfonylureas — Use with caution—discuss with your healthcare provider.
Caution:Insulin (without dose reduction) — Use with caution—discuss with your healthcare provider.

With supplements

Safe:Multivitamins — Generally safe to take alongside Mazdutide. Space doses apart if taking oral formulations to ensure optimal absorption.
Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Effectiveness

How do I know it's working?

Strong human trials · first signs weeks 1-4

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)

How it works

Mazdutide is a dual-action peptide that activates both glucagon receptors and GLP-1 receptors in your body, creating a synergistic weight loss effect more powerful than either mechanism alone.

It suppresses appetite through GLP-1 activation and increases metabolic rate through glucagon receptor activation, producing greater fat mobilization and weight loss compared to single-target GLP-1 drugs [5][18].

The deeper mechanism

Mazdutide is a synthetic peptide agonist that simultaneously activates glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R), both Gs-coupled GPCRs that increase cAMP and activate PKA signaling.

[5] GLP-1R activation in hypothalamic POMC neurons suppresses appetite and increases satiety signaling, while GcgR activation in hepatocytes and adipocytes increases gluconeogenesis, lipolysis, and fatty acid oxidation, increasing metabolic rate and energy expenditure.

[5][18] The dual agonism produces synergistic weight loss exceeding either mechanism alone: GLP-1 pathway provides appetite suppression (~15-20% weight loss), while GcgR activation provides metabolic acceleration (~8-12% additional weight loss), with combined effects potentially exceeding 20-25% weight loss in clinical trials.

Glucose-dependent insulin secretion enhancement occurs through both pathways, providing glycemic control benefits.

What to expect

Weeks 1-4
What you might notice
- Titration phase at 3 mg
- Early appetite reduction and mild gastrointestinal adjustment
- Initial weight loss of 2-4% typically observed
What's normal
- Full integration of Mazdutide into physiological systems is established
- Long-term Mazdutide response remains personalized to your physiology
- Mazdutide tolerance is well-maintained with consistent dosing
What's next
- Maintain your established Mazdutide protocol for sustained benefits
- Continue periodic monitoring to confirm Mazdutide efficacy
- Review comprehensive Mazdutide response with your provider
Weeks 4-16
What you might notice
- Dose escalation to 4.5-6 mg
- Progressive weight loss accelerates to 8-12%
- Significant HbA1c reductions become apparent in diabetic patients
What's normal
- Mazdutide is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Mazdutide's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Mazdutide dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 16-48+
What you might notice
- Maintenance at 6-9 mg
- Weight loss continues toward plateau of 15-20%
- Metabolic parameters stabilize with sustained improvements in lipids, liver fat, and blood pressure
What's normal
- Full therapeutic effects of Mazdutide are well-characterized at this point
- Maintenance of Mazdutide's therapeutic effects is typical
- Tolerance patterns with Mazdutide are generally stable over months
What's next
- Comprehensive assessment of Mazdutide efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

Improvement in the primary symptoms or condition being treated
Positive changes in relevant lab values or clinical markers
Consistent, stable response to Mazdutide over time
Reduction in symptom frequency or severity

General Well-being

Improved energy levels and daily functioning
Better quality of life related to the treated condition
Manageable or absent side effects indicating good tolerance
Positive feedback from healthcare provider during check-ups

Not seeing results? Common reasons

Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
Insufficient time at target dose—most compounds need several weeks to show full benefits
Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
Individual variation in response—genetics, metabolism, and other factors affect outcomes
Underlying conditions or medications interfering with absorption or effectiveness
Improper storage leading to degraded product—always verify proper storage conditions

Key research

2026[1]

“Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes”Guo L, et al.Finding: In Chinese adults with type 2 diabetes, mazdutide 6 mg achieved superior HbA1c reduction (-2.15%) and weight loss (-7.81%) compared to dulaglutide 1.5 mg. More participants reached HbA1c targets while maintaining safety.View study

2026[2]

“Mazdutide versus placebo in Chinese adults with type 2 diabetes”Zhu D, et al.Finding: Mazdutide monotherapy significantly reduced HbA1c by 2.15% and body weight by 7.81% versus placebo in diabetic patients after 24 weeks. More than 70% achieved both glycemic control and clinically meaningful weight loss.View study

2026[3]

“Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial”Luo Y, et al.Finding: The DREAMS-3 trial directly compared mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity. This first head-to-head trial targets HbA1c <7.0% with ≥10% weight reduction by week 32.View study

2025[4]

“Mazdutide: First Approval”Shirley M, et al.Finding: This review summarizes mazdutide's development and first regulatory approval. Mazdutide, a glucagon/GLP-1 receptor dual agonist, received first approval in China in June 2025 for weight management in adults with obesity or overweight, and its use was subsequently expanded to type 2 diabetes treatment.View study

2026[5]

“IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes”Elmendorf AJ, et al.Finding: This IUPHAR review examines the therapeutic repurposing of glucagon agonism for metabolic disease, providing mechanistic context for glucagon/GLP-1 dual agonists such as mazdutide in the treatment of obesity and type 2 diabetes.View study

2025[6]

“Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)”Ji L, et al. (New England Journal of Medicine)Finding: Phase 3 trial: once-weekly SC mazdutide titrated from 1.5 mg to maintenance 4 mg or 6 mg produced ~11-12% and ~13-15% mean body-weight reduction respectively over 32-48 weeks.View study

2026[7]

“Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial”Gao L, et al. (JAMA)Finding: Phase 3, 461 Chinese adults with obesity randomised 2:1 to once-weekly subcutaneous mazdutide 9 mg or placebo for 60 weeks. Mean body-weight change at week 60 was -16.65% with mazdutide versus -1.50% with placebo; 84.3% versus 33.1% lost at least 5%. Most common adverse events were vomiting (53.1% vs 1.3%), nausea (46.9% vs 3.2%) and diarrhoea (39.4% vs 6.5%), mostly mild to moderate; 2.9% discontinued for adverse events.View study

2025[8]

“Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints”Innovent BiologicsFinding: GLORY-2 topline: at week 60 the efficacy estimand showed mean weight reduction of 18.55% with mazdutide 9 mg versus 3.02% with placebo, and 20.08% in participants without type 2 diabetes versus 2.81% with placebo. 44.0% of the mazdutide group lost 20% or more of body weight (48.7% among those without diabetes). Gastrointestinal adverse events were mostly mild to moderate and transient.View study

2023[9]

“A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity”Ji L, et al. (Nature Communications)Finding: 248 Chinese overweight adults or adults with obesity randomised to once-weekly mazdutide 3 mg, 4.5 mg, 6 mg or placebo for 24 weeks. Mean body-weight change was -6.7%, -10.4% and -11.3% respectively versus +1.0% with placebo. Most common adverse events were diarrhoea, nausea and upper respiratory tract infection; lipase and amylase and calcitonin were monitored, with transient lipase elevations above three times the upper limit of normal in two participants and no calcitonin of 20 ng/L or higher.View study

2024[10]

“Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial”Zhang B, et al. (Diabetes Care)Finding: Adults with type 2 diabetes randomised to mazdutide 3 mg, 4.5 mg or 6 mg, open-label dulaglutide 1.5 mg, or placebo for 20 weeks. HbA1c fell 1.41% to 1.67% with mazdutide versus 1.35% with dulaglutide and +0.03% with placebo; body weight fell up to 7.1%. Most common adverse events with mazdutide were diarrhoea (36%), decreased appetite (29%), nausea (23%), vomiting (14%) and hypoglycaemia (10%); lipase, amylase and calcitonin were monitored.View study

2022[11]

“Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial”Ji L, et al. (EClinicalMedicine)Finding: Phase 1b multiple-ascending-dose trial of mazdutide titrated to 9 mg over 12 weeks and to 10 mg over 16 weeks. No serious adverse event was reported and all treatment-emergent adverse events were mild or moderate, most commonly upper respiratory tract infection, diarrhoea, decreased appetite, nausea, urinary tract infection, abdominal distension and vomiting. Mean body-weight change was -11.7% at week 12 in the 9 mg cohort and -9.5% at week 16 in the 10 mg cohort.View study

2026[12]

“Mazdutide 9 mg in Chinese adults with a body mass index >=30 kg/m2 but without diabetes: A phase 2 randomized controlled trial”Ji L, et al. (Med)Finding: 80 Chinese adults with BMI at least 30 kg/m2 and without diabetes randomised 3:1 to mazdutide 9 mg or placebo for 24 weeks. Mean body-weight change was -12.78% with mazdutide versus +1.80% with placebo; 81.7% lost at least 5%. Most common adverse events were nausea (50.0% vs 0%), diarrhoea (38.3% vs 10.0%) and vomiting (36.7% vs 10.0%), predominantly mild to moderate.View study

2022[13]

“A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes”Jiang H, et al. (Nature Communications)Finding: Phase 1b trial in 43 Chinese patients with type 2 diabetes given once-weekly IBI362 3.0 mg, 4.5 mg or 6.0 mg, placebo or dulaglutide 1.5 mg for 12 weeks. HbA1c, fasting plasma glucose and post-meal glucose fell from baseline in all three IBI362 cohorts. Most common treatment-emergent adverse events were diarrhoea (29.2%), decreased appetite (25.0%) and nausea (16.7%).View study

2026[14]

“Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial”Hsia SH, et al. (The Lancet Diabetes & Endocrinology)Finding: 179 US adults with obesity or overweight without type 2 diabetes randomised to once-weekly mazdutide 3-6 mg, 10 mg, 16 mg or placebo for 48 weeks. At 32 weeks least-squares mean body-weight change was -7.3%, -15.6% and -18.1% respectively versus -0.9% with placebo. Most common adverse events were gastrointestinal and mostly mild to moderate; discontinuation for adverse events was most frequent at 16 mg (20%), primarily gastrointestinal disorders.View study

2025[15]

“Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3”Innovent BiologicsFinding: DREAMS-3 topline: 48.0% of mazdutide 6 mg participants versus 21.0% of semaglutide 1 mg participants reached HbA1c below 7.0% with at least 10% weight reduction at week 32 (p<0.0001). Mean HbA1c change was -2.03% with mazdutide versus -1.84% with semaglutide (p<0.05) and mean weight change was -10.29% versus -6.00% (p<0.05).View study

2022[16]

“Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials”He L, et al. (JAMA Internal Medicine)Finding: 76 randomised trials and 103,371 patients. GLP-1 receptor agonist treatment was associated with increased risk of gallbladder or biliary disease (RR 1.37), cholelithiasis (RR 1.27), cholecystitis (RR 1.36) and biliary disease (RR 1.55). Risk was higher in weight-loss trials (RR 2.29), at higher doses (RR 1.56) and with longer duration of use (RR 1.40).View study

2024[17]

“WEGOVY (semaglutide) injection, for subcutaneous use — US prescribing information”Novo Nordisk / US Food and Drug AdministrationFinding: Section 5.2: acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising pancreatitis, has been observed in patients treated with GLP-1 receptor agonists; patients should be observed for persistent severe abdominal pain, sometimes radiating to the back, and treatment discontinued promptly if pancreatitis is suspected and not restarted if confirmed. Section 5.3: acute gallbladder disease has occurred, and substantial or rapid weight loss can increase the risk of gallstones.View study

2025[18]

“Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions”Neff GW (Diabetes, Obesity and Metabolism)Finding: Review of glucagon receptor signalling: glucagon stimulates lipolysis and mitochondrial fat oxidation in the liver, reduces caloric intake and increases energy expenditure, and glucagon receptor antagonism raises body weight, hepatic fat and serum lipids. GCGR/GLP-1 multi-agonists including mazdutide combine this with GLP-1 receptor agonism, producing weight loss while improving liver health in metabolic dysfunction-associated steatotic liver disease.View study

Clinical trials

Tested in people

41 registered studies, 20 still enrolling.

41registered studies

20recruiting now

15phase 3 or 4

9with published results

By phase

Phase 311

Phase 19

Phase 28

Phase 1/24

Phase 43

Phase 2/31

No phase5

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug41

Records only0

About 11,035 people took part in the studies that actually administered Mazdutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.

Most recent

NCT07781150Phase 2Not Yet Recruiting128 enrolled
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
Tongji Hospital
NCT07767552Not Yet Recruiting249 enrolled
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
Yanbing Li
NCT07713992Not Yet Recruiting72 enrolled
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Tianjin Medical University

See all 41 trials for Mazdutide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Mazdutide is named as an intervention; studies that only mention it in passing are not.

Questions

Frequently asked

How does mazdutide differ from semaglutide?

Mazdutide is a dual GLP-1/glucagon receptor agonist, while semaglutide selectively targets only the GLP-1 receptor. [4][5] The additional glucagon receptor activation in mazdutide increases hepatic fat oxidation and energy expenditure, potentially offering enhanced weight loss and liver fat reduction. [5][18] In the DREAMS-3 head-to-head trial, mazdutide demonstrated statistically superior HbA1c reductions compared to semaglutide 1 mg [3][15].

Is mazdutide approved by the FDA?

As of early 2026, mazdutide is not FDA-approved. It received approval from China's NMPA in June 2025 for chronic weight management and in September 2025 for type 2 diabetes, marketed as Xinermei. Regulatory submissions in other markets are anticipated based on ongoing global clinical programs [4].

What was the weight loss observed in clinical trials?

In the GLORY-2 Phase 3 trial, mazdutide 9 mg achieved up to 20.1% mean body weight loss over the treatment period in adults with obesity. [7][8] Earlier Phase 2 studies showed dose-dependent weight loss ranging from approximately 10% to 17% across dose groups [9][12][14].

Does mazdutide require dose titration?

Yes. Mazdutide is initiated at 3 mg once weekly and gradually titrated upward through 4.5 mg and 6 mg to the target maintenance dose of up to 9 mg. [9][10][12] This stepwise approach minimizes gastrointestinal side effects, particularly nausea and vomiting.

Can mazdutide be used for type 2 diabetes?

Yes. Mazdutide is approved in China for type 2 diabetes [4] and has demonstrated superior HbA1c reductions compared to both dulaglutide and semaglutide in Phase 3 DREAMS trials. [1][15] Its dual mechanism provides glycemic control through both enhanced insulin secretion and reduced hepatic glucose output [5].

What are the main advantages of dual receptor agonism?

Dual GLP-1/glucagon receptor agonism combines appetite suppression and glucose regulation from GLP-1 activation with increased energy expenditure, hepatic fat oxidation, and lipid metabolism enhancement from glucagon activation. This complementary mechanism may produce greater weight loss and more comprehensive metabolic improvement than selective GLP-1 agonists alone [5][18].

History & related research

History · since 2018

The Chinese Biotech That Beat The World to a New Drug Class

A young Chinese company races against global giants to develop the world's first dual GLP-1/glucagon agonist. In a stunning upset, Innovent Biologics reaches the finish line first — winning approval in China in June 2025 and proving that Asia's biotech industry has arrived on the world stage.

Read the full history of Mazdutide

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Mazdutide, on one page.

Mazdutide dosing protocol

Peptide Database